NCT01649791View on ClinicalTrials.gov

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

NATerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

October 31, 2014

Conditions
B-cell Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic Leukemia
Interventions
DRUG

lenalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative study

PROCEDURE

lymph node biopsy

Correlative study

PROCEDURE

bone marrow aspiration

Correlative study

OTHER

pharmacological study

Correlative study

OTHER

flow cytometry

Correlative study

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER